Review



hpv 16 e7 fragment  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Addgene inc hpv 16 e7 fragment
    A. Table of patient samples used in snRNA-seq, with the status of a few gene alterations listed. B. Sample MRIs from one patient showing T1 contrast-enhanced and T2 weighted images. On the left is the preoperative study demonstrating location of contrast enhancing zone (yellow arrow) containing the presumed solid tumor and the broader, T2-hyperintense signal (red arrow) that containing the presumed infiltrating tumor. The middle image shows the pre-operative regions selected for biopsy and the right image shows the intraoperative neuronavigation biopsy acquisition. C. The workflow from sample biopsy, processing, snRNA-sequencing, and data analysis. D. Bar plots of cell type proportions in the infiltrating and solid tumor regions. Each bar represents the mean proportion of the selected cell type in the region and the positive and negative standard deviation are represented by the bracket. Each dot represents the cell type proportion of a single sample. E. Representative images of expanded Nf1- knockout OPCs (GFP + PDGFRα + ) generated by transduction of MSCV carrying Nf1 guide RNA/Cas9. WT OPCs (GFP - PDGFRα + ) were excluded from the expanded Nf1 -null OPC clones, suggesting OPC competition. Scale bar: 50 μm. F. Representative images of expanded Rb -inactivated OPCs (GFP + PDGFRα + ) upon transduction of MSCV <t>carrying</t> <t>HPV-16</t> E7 protein that inactivates Rb function. Expanded GFP + Rb -inactivated OPCs (orange arrow) intermixed with WT OPCs (GFP - PDGFRα + , white arrow-head), suggesting the lack of OPC competition. Scale bar: 50 μm G. Representative images showing the expansion of OPCs with EGFR mutation ( EGFRvIII ). The expanded clone of EGFRvIII -expressing OPCs excluded WT OPCs (GFP - PDGFRα + ), suggesting OPC competition. Scale bar: 50 μm. H. Summary of the sufficiency and insufficiency in driving OPC competition of all examined gliomagenic mutations in this study.
    Hpv 16 E7 Fragment, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hpv 16 e7 fragment/product/Addgene inc
    Average 93 stars, based on 3 article reviews
    hpv 16 e7 fragment - by Bioz Stars, 2026-06
    93/100 stars

    Images

    1) Product Images from "Critical role of cell competition in gliomagenesis"

    Article Title: Critical role of cell competition in gliomagenesis

    Journal: bioRxiv

    doi: 10.64898/2026.01.15.699808

    A. Table of patient samples used in snRNA-seq, with the status of a few gene alterations listed. B. Sample MRIs from one patient showing T1 contrast-enhanced and T2 weighted images. On the left is the preoperative study demonstrating location of contrast enhancing zone (yellow arrow) containing the presumed solid tumor and the broader, T2-hyperintense signal (red arrow) that containing the presumed infiltrating tumor. The middle image shows the pre-operative regions selected for biopsy and the right image shows the intraoperative neuronavigation biopsy acquisition. C. The workflow from sample biopsy, processing, snRNA-sequencing, and data analysis. D. Bar plots of cell type proportions in the infiltrating and solid tumor regions. Each bar represents the mean proportion of the selected cell type in the region and the positive and negative standard deviation are represented by the bracket. Each dot represents the cell type proportion of a single sample. E. Representative images of expanded Nf1- knockout OPCs (GFP + PDGFRα + ) generated by transduction of MSCV carrying Nf1 guide RNA/Cas9. WT OPCs (GFP - PDGFRα + ) were excluded from the expanded Nf1 -null OPC clones, suggesting OPC competition. Scale bar: 50 μm. F. Representative images of expanded Rb -inactivated OPCs (GFP + PDGFRα + ) upon transduction of MSCV carrying HPV-16 E7 protein that inactivates Rb function. Expanded GFP + Rb -inactivated OPCs (orange arrow) intermixed with WT OPCs (GFP - PDGFRα + , white arrow-head), suggesting the lack of OPC competition. Scale bar: 50 μm G. Representative images showing the expansion of OPCs with EGFR mutation ( EGFRvIII ). The expanded clone of EGFRvIII -expressing OPCs excluded WT OPCs (GFP - PDGFRα + ), suggesting OPC competition. Scale bar: 50 μm. H. Summary of the sufficiency and insufficiency in driving OPC competition of all examined gliomagenic mutations in this study.
    Figure Legend Snippet: A. Table of patient samples used in snRNA-seq, with the status of a few gene alterations listed. B. Sample MRIs from one patient showing T1 contrast-enhanced and T2 weighted images. On the left is the preoperative study demonstrating location of contrast enhancing zone (yellow arrow) containing the presumed solid tumor and the broader, T2-hyperintense signal (red arrow) that containing the presumed infiltrating tumor. The middle image shows the pre-operative regions selected for biopsy and the right image shows the intraoperative neuronavigation biopsy acquisition. C. The workflow from sample biopsy, processing, snRNA-sequencing, and data analysis. D. Bar plots of cell type proportions in the infiltrating and solid tumor regions. Each bar represents the mean proportion of the selected cell type in the region and the positive and negative standard deviation are represented by the bracket. Each dot represents the cell type proportion of a single sample. E. Representative images of expanded Nf1- knockout OPCs (GFP + PDGFRα + ) generated by transduction of MSCV carrying Nf1 guide RNA/Cas9. WT OPCs (GFP - PDGFRα + ) were excluded from the expanded Nf1 -null OPC clones, suggesting OPC competition. Scale bar: 50 μm. F. Representative images of expanded Rb -inactivated OPCs (GFP + PDGFRα + ) upon transduction of MSCV carrying HPV-16 E7 protein that inactivates Rb function. Expanded GFP + Rb -inactivated OPCs (orange arrow) intermixed with WT OPCs (GFP - PDGFRα + , white arrow-head), suggesting the lack of OPC competition. Scale bar: 50 μm G. Representative images showing the expansion of OPCs with EGFR mutation ( EGFRvIII ). The expanded clone of EGFRvIII -expressing OPCs excluded WT OPCs (GFP - PDGFRα + ), suggesting OPC competition. Scale bar: 50 μm. H. Summary of the sufficiency and insufficiency in driving OPC competition of all examined gliomagenic mutations in this study.

    Techniques Used: Sequencing, Standard Deviation, Knock-Out, Generated, Transduction, Clone Assay, Mutagenesis, Expressing



    Similar Products

    94
    ATCC hpv 16 e6 e7
    Hpv 16 E6 E7, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hpv 16 e6 e7/product/ATCC
    Average 94 stars, based on 1 article reviews
    hpv 16 e6 e7 - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    93
    Sino Biological recombinant hpv16 e7 protein
    A) Generation of monocyte-derived DCs from head and neck squamous cell carcinoma (HNSCC) patients. Plot on left shows representative flow cytometric staining of freshly isolated monocytes; right plot shows DC-like phenotype after 3 days of culture in medium containing GM-CSF and IL-4. Graph on right shows expression of key differentiation markers, symbols show results from different patient samples, bars show means. B) Co-incubation of HNSCC patient DCs with allogeneic iNKT cells from healthy donors results in formation of tightly-adhered iNKT-DC conjugates. Plot on left shows representative flow cytometric staining; graph on right shows percent of DCs in conjugates, symbols show results from different donors, bars show means. C) Conjugation of HNSCC patient DCs with iNKT cells leads to increased expression of key T cell activating ligands. Paired symbols show results for DCs alone vs. iNKT-DC conjugates from the same patient; points below dotted line did not have positive staining. P values by Wilcoxon matched pairs t-test. D) CFSE-labeled T cells from blood of <t>HPV16</t> + HNSCC patients were cultured in the indicated conditions in the presence or absence of recombinant HPV E7 protein. Graphs show percent of CD4 or CD8 T cells that had undergone cell division after 10 days. Pairings show +/− antigen conditions from the same experiment; P values calculated by Wilcoxon match pairs signed rank test. E) Plots showing flow cytometric analysis of CD8 + T cells from one representative experiment out of seven. T cells cultured with E7 antigen are shown in filled histograms (top percentages); cultures without E7 antigen shown by dotted lines (bottom percentages). F) Tetramer staining of T cells from HLA-A2 + patients. Plots on left show staining for CTV and HPV E7 peptide-loaded HLA-A2 tetramer after gating on live cells expressing CD3 and CD8β. Graph on right shows data from 3 HLA-A2 + patients on the percent tetramer positive of proliferated CD8 + T cells after 10 days of culture with DCs alone or iNKT-DCs in the absence (light symbols) or presence (dark symbols) of recombinant E7 antigen. P values by paired t-test.
    Recombinant Hpv16 E7 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant hpv16 e7 protein/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    recombinant hpv16 e7 protein - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    95
    Santa Cruz Biotechnology anti phospho hpv 16 e7
    A) Generation of monocyte-derived DCs from head and neck squamous cell carcinoma (HNSCC) patients. Plot on left shows representative flow cytometric staining of freshly isolated monocytes; right plot shows DC-like phenotype after 3 days of culture in medium containing GM-CSF and IL-4. Graph on right shows expression of key differentiation markers, symbols show results from different patient samples, bars show means. B) Co-incubation of HNSCC patient DCs with allogeneic iNKT cells from healthy donors results in formation of tightly-adhered iNKT-DC conjugates. Plot on left shows representative flow cytometric staining; graph on right shows percent of DCs in conjugates, symbols show results from different donors, bars show means. C) Conjugation of HNSCC patient DCs with iNKT cells leads to increased expression of key T cell activating ligands. Paired symbols show results for DCs alone vs. iNKT-DC conjugates from the same patient; points below dotted line did not have positive staining. P values by Wilcoxon matched pairs t-test. D) CFSE-labeled T cells from blood of <t>HPV16</t> + HNSCC patients were cultured in the indicated conditions in the presence or absence of recombinant HPV E7 protein. Graphs show percent of CD4 or CD8 T cells that had undergone cell division after 10 days. Pairings show +/− antigen conditions from the same experiment; P values calculated by Wilcoxon match pairs signed rank test. E) Plots showing flow cytometric analysis of CD8 + T cells from one representative experiment out of seven. T cells cultured with E7 antigen are shown in filled histograms (top percentages); cultures without E7 antigen shown by dotted lines (bottom percentages). F) Tetramer staining of T cells from HLA-A2 + patients. Plots on left show staining for CTV and HPV E7 peptide-loaded HLA-A2 tetramer after gating on live cells expressing CD3 and CD8β. Graph on right shows data from 3 HLA-A2 + patients on the percent tetramer positive of proliferated CD8 + T cells after 10 days of culture with DCs alone or iNKT-DCs in the absence (light symbols) or presence (dark symbols) of recombinant E7 antigen. P values by paired t-test.
    Anti Phospho Hpv 16 E7, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti phospho hpv 16 e7/product/Santa Cruz Biotechnology
    Average 95 stars, based on 1 article reviews
    anti phospho hpv 16 e7 - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    95
    Santa Cruz Biotechnology anti hpv 16 e7
    A) Generation of monocyte-derived DCs from head and neck squamous cell carcinoma (HNSCC) patients. Plot on left shows representative flow cytometric staining of freshly isolated monocytes; right plot shows DC-like phenotype after 3 days of culture in medium containing GM-CSF and IL-4. Graph on right shows expression of key differentiation markers, symbols show results from different patient samples, bars show means. B) Co-incubation of HNSCC patient DCs with allogeneic iNKT cells from healthy donors results in formation of tightly-adhered iNKT-DC conjugates. Plot on left shows representative flow cytometric staining; graph on right shows percent of DCs in conjugates, symbols show results from different donors, bars show means. C) Conjugation of HNSCC patient DCs with iNKT cells leads to increased expression of key T cell activating ligands. Paired symbols show results for DCs alone vs. iNKT-DC conjugates from the same patient; points below dotted line did not have positive staining. P values by Wilcoxon matched pairs t-test. D) CFSE-labeled T cells from blood of <t>HPV16</t> + HNSCC patients were cultured in the indicated conditions in the presence or absence of recombinant HPV E7 protein. Graphs show percent of CD4 or CD8 T cells that had undergone cell division after 10 days. Pairings show +/− antigen conditions from the same experiment; P values calculated by Wilcoxon match pairs signed rank test. E) Plots showing flow cytometric analysis of CD8 + T cells from one representative experiment out of seven. T cells cultured with E7 antigen are shown in filled histograms (top percentages); cultures without E7 antigen shown by dotted lines (bottom percentages). F) Tetramer staining of T cells from HLA-A2 + patients. Plots on left show staining for CTV and HPV E7 peptide-loaded HLA-A2 tetramer after gating on live cells expressing CD3 and CD8β. Graph on right shows data from 3 HLA-A2 + patients on the percent tetramer positive of proliferated CD8 + T cells after 10 days of culture with DCs alone or iNKT-DCs in the absence (light symbols) or presence (dark symbols) of recombinant E7 antigen. P values by paired t-test.
    Anti Hpv 16 E7, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti hpv 16 e7/product/Santa Cruz Biotechnology
    Average 95 stars, based on 1 article reviews
    anti hpv 16 e7 - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    86
    Eurofins hpv 16 e6 e7
    (a) Schematic of <t>the</t> <t>HPV-16</t> E7 CR2 region showing the Casein Kinase II (CKII) phosphorylation site at serines 31 and 32/33. (b) Sequences of biotin-tagged peptides corresponding to the HPV-16 E7 CR2 region, synthesized in phosphorylated and non-phosphorylated forms and used as bait in peptide pulldown assays. (c) Mass spectrometry analysis of HaCaT lysates pulled down with phosphorylated or non-phosphorylated E7 peptides. The phosphorylated peptide enriched known E7 interactor pRB and selectively precipitated Vangl1. (d) GST pulldown assays showing strong binding of endogenous Vangl1 to phosphorylated HPV-16 E7, with weak or undetectable binding to HPV-11 E7, non-phosphorylated HPV-16 or HPV-18 E7, phosphorylated HPV-18 E7, or HPV-5 E7. ‘P’ indicates phosphorylated forms of the respective E7s. (e) Co-immunoprecipitation of FLAG-Vangl1 with FLAG/HA-tagged HPV-16 E7 expressed in HEK293 cells confirms the in vivo interaction. Beta galactosidase (β-gal) protein expression is used as a loading control in the western blotting analyses. (f) TCGA analysis shows that Vangl1 expression is associated with increased clinical risk in multiple tumour types, including cervical and endocervical cancer (CESC), lower-grade glioma (LGG), lung adenocarcinoma (LUAD), and pancreatic adenocarcinoma (PAAD). The statistical significance is represented as z-score and p -value.
    Hpv 16 E6 E7, supplied by Eurofins, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hpv 16 e6 e7/product/Eurofins
    Average 86 stars, based on 1 article reviews
    hpv 16 e6 e7 - by Bioz Stars, 2026-06
    86/100 stars
      Buy from Supplier

    93
    Addgene inc hpv 16 e7 fragment
    A. Table of patient samples used in snRNA-seq, with the status of a few gene alterations listed. B. Sample MRIs from one patient showing T1 contrast-enhanced and T2 weighted images. On the left is the preoperative study demonstrating location of contrast enhancing zone (yellow arrow) containing the presumed solid tumor and the broader, T2-hyperintense signal (red arrow) that containing the presumed infiltrating tumor. The middle image shows the pre-operative regions selected for biopsy and the right image shows the intraoperative neuronavigation biopsy acquisition. C. The workflow from sample biopsy, processing, snRNA-sequencing, and data analysis. D. Bar plots of cell type proportions in the infiltrating and solid tumor regions. Each bar represents the mean proportion of the selected cell type in the region and the positive and negative standard deviation are represented by the bracket. Each dot represents the cell type proportion of a single sample. E. Representative images of expanded Nf1- knockout OPCs (GFP + PDGFRα + ) generated by transduction of MSCV carrying Nf1 guide RNA/Cas9. WT OPCs (GFP - PDGFRα + ) were excluded from the expanded Nf1 -null OPC clones, suggesting OPC competition. Scale bar: 50 μm. F. Representative images of expanded Rb -inactivated OPCs (GFP + PDGFRα + ) upon transduction of MSCV <t>carrying</t> <t>HPV-16</t> E7 protein that inactivates Rb function. Expanded GFP + Rb -inactivated OPCs (orange arrow) intermixed with WT OPCs (GFP - PDGFRα + , white arrow-head), suggesting the lack of OPC competition. Scale bar: 50 μm G. Representative images showing the expansion of OPCs with EGFR mutation ( EGFRvIII ). The expanded clone of EGFRvIII -expressing OPCs excluded WT OPCs (GFP - PDGFRα + ), suggesting OPC competition. Scale bar: 50 μm. H. Summary of the sufficiency and insufficiency in driving OPC competition of all examined gliomagenic mutations in this study.
    Hpv 16 E7 Fragment, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hpv 16 e7 fragment/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    hpv 16 e7 fragment - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    93
    Addgene inc plasmid p1324 hpv 16 e7
    A. Table of patient samples used in snRNA-seq, with the status of a few gene alterations listed. B. Sample MRIs from one patient showing T1 contrast-enhanced and T2 weighted images. On the left is the preoperative study demonstrating location of contrast enhancing zone (yellow arrow) containing the presumed solid tumor and the broader, T2-hyperintense signal (red arrow) that containing the presumed infiltrating tumor. The middle image shows the pre-operative regions selected for biopsy and the right image shows the intraoperative neuronavigation biopsy acquisition. C. The workflow from sample biopsy, processing, snRNA-sequencing, and data analysis. D. Bar plots of cell type proportions in the infiltrating and solid tumor regions. Each bar represents the mean proportion of the selected cell type in the region and the positive and negative standard deviation are represented by the bracket. Each dot represents the cell type proportion of a single sample. E. Representative images of expanded Nf1- knockout OPCs (GFP + PDGFRα + ) generated by transduction of MSCV carrying Nf1 guide RNA/Cas9. WT OPCs (GFP - PDGFRα + ) were excluded from the expanded Nf1 -null OPC clones, suggesting OPC competition. Scale bar: 50 μm. F. Representative images of expanded Rb -inactivated OPCs (GFP + PDGFRα + ) upon transduction of MSCV <t>carrying</t> <t>HPV-16</t> E7 protein that inactivates Rb function. Expanded GFP + Rb -inactivated OPCs (orange arrow) intermixed with WT OPCs (GFP - PDGFRα + , white arrow-head), suggesting the lack of OPC competition. Scale bar: 50 μm G. Representative images showing the expansion of OPCs with EGFR mutation ( EGFRvIII ). The expanded clone of EGFRvIII -expressing OPCs excluded WT OPCs (GFP - PDGFRα + ), suggesting OPC competition. Scale bar: 50 μm. H. Summary of the sufficiency and insufficiency in driving OPC competition of all examined gliomagenic mutations in this study.
    Plasmid P1324 Hpv 16 E7, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasmid p1324 hpv 16 e7/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    plasmid p1324 hpv 16 e7 - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    93
    Addgene inc p1321 hpv16 e6 e7
    A. Table of patient samples used in snRNA-seq, with the status of a few gene alterations listed. B. Sample MRIs from one patient showing T1 contrast-enhanced and T2 weighted images. On the left is the preoperative study demonstrating location of contrast enhancing zone (yellow arrow) containing the presumed solid tumor and the broader, T2-hyperintense signal (red arrow) that containing the presumed infiltrating tumor. The middle image shows the pre-operative regions selected for biopsy and the right image shows the intraoperative neuronavigation biopsy acquisition. C. The workflow from sample biopsy, processing, snRNA-sequencing, and data analysis. D. Bar plots of cell type proportions in the infiltrating and solid tumor regions. Each bar represents the mean proportion of the selected cell type in the region and the positive and negative standard deviation are represented by the bracket. Each dot represents the cell type proportion of a single sample. E. Representative images of expanded Nf1- knockout OPCs (GFP + PDGFRα + ) generated by transduction of MSCV carrying Nf1 guide RNA/Cas9. WT OPCs (GFP - PDGFRα + ) were excluded from the expanded Nf1 -null OPC clones, suggesting OPC competition. Scale bar: 50 μm. F. Representative images of expanded Rb -inactivated OPCs (GFP + PDGFRα + ) upon transduction of MSCV <t>carrying</t> <t>HPV-16</t> E7 protein that inactivates Rb function. Expanded GFP + Rb -inactivated OPCs (orange arrow) intermixed with WT OPCs (GFP - PDGFRα + , white arrow-head), suggesting the lack of OPC competition. Scale bar: 50 μm G. Representative images showing the expansion of OPCs with EGFR mutation ( EGFRvIII ). The expanded clone of EGFRvIII -expressing OPCs excluded WT OPCs (GFP - PDGFRα + ), suggesting OPC competition. Scale bar: 50 μm. H. Summary of the sufficiency and insufficiency in driving OPC competition of all examined gliomagenic mutations in this study.
    P1321 Hpv16 E6 E7, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p1321 hpv16 e6 e7/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    p1321 hpv16 e6 e7 - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    86
    Azenta hpv 16 18 e6 e7
    A. Table of patient samples used in snRNA-seq, with the status of a few gene alterations listed. B. Sample MRIs from one patient showing T1 contrast-enhanced and T2 weighted images. On the left is the preoperative study demonstrating location of contrast enhancing zone (yellow arrow) containing the presumed solid tumor and the broader, T2-hyperintense signal (red arrow) that containing the presumed infiltrating tumor. The middle image shows the pre-operative regions selected for biopsy and the right image shows the intraoperative neuronavigation biopsy acquisition. C. The workflow from sample biopsy, processing, snRNA-sequencing, and data analysis. D. Bar plots of cell type proportions in the infiltrating and solid tumor regions. Each bar represents the mean proportion of the selected cell type in the region and the positive and negative standard deviation are represented by the bracket. Each dot represents the cell type proportion of a single sample. E. Representative images of expanded Nf1- knockout OPCs (GFP + PDGFRα + ) generated by transduction of MSCV carrying Nf1 guide RNA/Cas9. WT OPCs (GFP - PDGFRα + ) were excluded from the expanded Nf1 -null OPC clones, suggesting OPC competition. Scale bar: 50 μm. F. Representative images of expanded Rb -inactivated OPCs (GFP + PDGFRα + ) upon transduction of MSCV <t>carrying</t> <t>HPV-16</t> E7 protein that inactivates Rb function. Expanded GFP + Rb -inactivated OPCs (orange arrow) intermixed with WT OPCs (GFP - PDGFRα + , white arrow-head), suggesting the lack of OPC competition. Scale bar: 50 μm G. Representative images showing the expansion of OPCs with EGFR mutation ( EGFRvIII ). The expanded clone of EGFRvIII -expressing OPCs excluded WT OPCs (GFP - PDGFRα + ), suggesting OPC competition. Scale bar: 50 μm. H. Summary of the sufficiency and insufficiency in driving OPC competition of all examined gliomagenic mutations in this study.
    Hpv 16 18 E6 E7, supplied by Azenta, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hpv 16 18 e6 e7/product/Azenta
    Average 86 stars, based on 1 article reviews
    hpv 16 18 e6 e7 - by Bioz Stars, 2026-06
    86/100 stars
      Buy from Supplier

    Image Search Results


    A) Generation of monocyte-derived DCs from head and neck squamous cell carcinoma (HNSCC) patients. Plot on left shows representative flow cytometric staining of freshly isolated monocytes; right plot shows DC-like phenotype after 3 days of culture in medium containing GM-CSF and IL-4. Graph on right shows expression of key differentiation markers, symbols show results from different patient samples, bars show means. B) Co-incubation of HNSCC patient DCs with allogeneic iNKT cells from healthy donors results in formation of tightly-adhered iNKT-DC conjugates. Plot on left shows representative flow cytometric staining; graph on right shows percent of DCs in conjugates, symbols show results from different donors, bars show means. C) Conjugation of HNSCC patient DCs with iNKT cells leads to increased expression of key T cell activating ligands. Paired symbols show results for DCs alone vs. iNKT-DC conjugates from the same patient; points below dotted line did not have positive staining. P values by Wilcoxon matched pairs t-test. D) CFSE-labeled T cells from blood of HPV16 + HNSCC patients were cultured in the indicated conditions in the presence or absence of recombinant HPV E7 protein. Graphs show percent of CD4 or CD8 T cells that had undergone cell division after 10 days. Pairings show +/− antigen conditions from the same experiment; P values calculated by Wilcoxon match pairs signed rank test. E) Plots showing flow cytometric analysis of CD8 + T cells from one representative experiment out of seven. T cells cultured with E7 antigen are shown in filled histograms (top percentages); cultures without E7 antigen shown by dotted lines (bottom percentages). F) Tetramer staining of T cells from HLA-A2 + patients. Plots on left show staining for CTV and HPV E7 peptide-loaded HLA-A2 tetramer after gating on live cells expressing CD3 and CD8β. Graph on right shows data from 3 HLA-A2 + patients on the percent tetramer positive of proliferated CD8 + T cells after 10 days of culture with DCs alone or iNKT-DCs in the absence (light symbols) or presence (dark symbols) of recombinant E7 antigen. P values by paired t-test.

    Journal: Cancer immunology research

    Article Title: CD8 + T cell antitumor immunity via human iNKT-DC conjugates

    doi: 10.1158/2326-6066.CIR-25-0454

    Figure Lengend Snippet: A) Generation of monocyte-derived DCs from head and neck squamous cell carcinoma (HNSCC) patients. Plot on left shows representative flow cytometric staining of freshly isolated monocytes; right plot shows DC-like phenotype after 3 days of culture in medium containing GM-CSF and IL-4. Graph on right shows expression of key differentiation markers, symbols show results from different patient samples, bars show means. B) Co-incubation of HNSCC patient DCs with allogeneic iNKT cells from healthy donors results in formation of tightly-adhered iNKT-DC conjugates. Plot on left shows representative flow cytometric staining; graph on right shows percent of DCs in conjugates, symbols show results from different donors, bars show means. C) Conjugation of HNSCC patient DCs with iNKT cells leads to increased expression of key T cell activating ligands. Paired symbols show results for DCs alone vs. iNKT-DC conjugates from the same patient; points below dotted line did not have positive staining. P values by Wilcoxon matched pairs t-test. D) CFSE-labeled T cells from blood of HPV16 + HNSCC patients were cultured in the indicated conditions in the presence or absence of recombinant HPV E7 protein. Graphs show percent of CD4 or CD8 T cells that had undergone cell division after 10 days. Pairings show +/− antigen conditions from the same experiment; P values calculated by Wilcoxon match pairs signed rank test. E) Plots showing flow cytometric analysis of CD8 + T cells from one representative experiment out of seven. T cells cultured with E7 antigen are shown in filled histograms (top percentages); cultures without E7 antigen shown by dotted lines (bottom percentages). F) Tetramer staining of T cells from HLA-A2 + patients. Plots on left show staining for CTV and HPV E7 peptide-loaded HLA-A2 tetramer after gating on live cells expressing CD3 and CD8β. Graph on right shows data from 3 HLA-A2 + patients on the percent tetramer positive of proliferated CD8 + T cells after 10 days of culture with DCs alone or iNKT-DCs in the absence (light symbols) or presence (dark symbols) of recombinant E7 antigen. P values by paired t-test.

    Article Snippet: Antigen preparations used were inactivated EBV (equivalent to 2.5U EBV/1000 DC), or 5ng/ml dialyzed recombinant HPV16 E7 protein (Sino Biological Cat# 40965-V07E).

    Techniques: Activation Assay, Derivative Assay, Staining, Isolation, Expressing, Incubation, Conjugation Assay, Labeling, Cell Culture, Recombinant

    (a) Schematic of the HPV-16 E7 CR2 region showing the Casein Kinase II (CKII) phosphorylation site at serines 31 and 32/33. (b) Sequences of biotin-tagged peptides corresponding to the HPV-16 E7 CR2 region, synthesized in phosphorylated and non-phosphorylated forms and used as bait in peptide pulldown assays. (c) Mass spectrometry analysis of HaCaT lysates pulled down with phosphorylated or non-phosphorylated E7 peptides. The phosphorylated peptide enriched known E7 interactor pRB and selectively precipitated Vangl1. (d) GST pulldown assays showing strong binding of endogenous Vangl1 to phosphorylated HPV-16 E7, with weak or undetectable binding to HPV-11 E7, non-phosphorylated HPV-16 or HPV-18 E7, phosphorylated HPV-18 E7, or HPV-5 E7. ‘P’ indicates phosphorylated forms of the respective E7s. (e) Co-immunoprecipitation of FLAG-Vangl1 with FLAG/HA-tagged HPV-16 E7 expressed in HEK293 cells confirms the in vivo interaction. Beta galactosidase (β-gal) protein expression is used as a loading control in the western blotting analyses. (f) TCGA analysis shows that Vangl1 expression is associated with increased clinical risk in multiple tumour types, including cervical and endocervical cancer (CESC), lower-grade glioma (LGG), lung adenocarcinoma (LUAD), and pancreatic adenocarcinoma (PAAD). The statistical significance is represented as z-score and p -value.

    Journal: bioRxiv

    Article Title: CKII-Phosphorylated HPV-16 E7 Disrupts Planar Cell Polarity by Recruiting Vangl1 Phospho-E7 Hijacks Vangl1 Trafficking

    doi: 10.64898/2026.02.25.707969

    Figure Lengend Snippet: (a) Schematic of the HPV-16 E7 CR2 region showing the Casein Kinase II (CKII) phosphorylation site at serines 31 and 32/33. (b) Sequences of biotin-tagged peptides corresponding to the HPV-16 E7 CR2 region, synthesized in phosphorylated and non-phosphorylated forms and used as bait in peptide pulldown assays. (c) Mass spectrometry analysis of HaCaT lysates pulled down with phosphorylated or non-phosphorylated E7 peptides. The phosphorylated peptide enriched known E7 interactor pRB and selectively precipitated Vangl1. (d) GST pulldown assays showing strong binding of endogenous Vangl1 to phosphorylated HPV-16 E7, with weak or undetectable binding to HPV-11 E7, non-phosphorylated HPV-16 or HPV-18 E7, phosphorylated HPV-18 E7, or HPV-5 E7. ‘P’ indicates phosphorylated forms of the respective E7s. (e) Co-immunoprecipitation of FLAG-Vangl1 with FLAG/HA-tagged HPV-16 E7 expressed in HEK293 cells confirms the in vivo interaction. Beta galactosidase (β-gal) protein expression is used as a loading control in the western blotting analyses. (f) TCGA analysis shows that Vangl1 expression is associated with increased clinical risk in multiple tumour types, including cervical and endocervical cancer (CESC), lower-grade glioma (LGG), lung adenocarcinoma (LUAD), and pancreatic adenocarcinoma (PAAD). The statistical significance is represented as z-score and p -value.

    Article Snippet: CaSki, HeLa, C-33A and HaCaT cells were transfected with siRNAs targeting Vangl1 (Dharmacon SMARTpool), AP1M1 (Dharmacon SMARTpool), HPV-16 E6/E7 (Eurofins), or Scramble control (Dharmacon siSTABLE) as previously described ( ).

    Techniques: Phospho-proteomics, Synthesized, Mass Spectrometry, Binding Assay, Immunoprecipitation, In Vivo, Expressing, Control, Western Blot

    (a) Co-immunoprecipitation of FLAG-tagged Vangl1 or Vangl2 with FLAG/HA-tagged HPV-16 E7 expressed in HEK293 cells. HPV-16 E7 binds strongly to Vangl1 but only minimally to Vangl2. (b) Peptide pulldown assays using phosphorylated and non-phosphorylated HPV-16 E7 N29S CR2 peptides. Vangl1 binds strongly to the phosphorylated N29S peptide but not to its non-phosphorylated form. (c) Pulldown assays using phosphomimic HPV-16 E7 CR2 peptides in which CKII-targeted serines were substituted with aspartic acid. The phosphomimic fails to bind Vangl1. ‘ p’ indicates phosphorylation. (d) Co-immunoprecipitation of FLAG-Vangl1 with FLAG/HA-tagged HPV-16 E7 in HEK293 cells treated with the CKII inhibitor CX-4945. CKII inhibition markedly reduces Vangl1–E7 association. Beta galactosidase (β-gal) protein expression is used as a loading control in the western blotting analyses.

    Journal: bioRxiv

    Article Title: CKII-Phosphorylated HPV-16 E7 Disrupts Planar Cell Polarity by Recruiting Vangl1 Phospho-E7 Hijacks Vangl1 Trafficking

    doi: 10.64898/2026.02.25.707969

    Figure Lengend Snippet: (a) Co-immunoprecipitation of FLAG-tagged Vangl1 or Vangl2 with FLAG/HA-tagged HPV-16 E7 expressed in HEK293 cells. HPV-16 E7 binds strongly to Vangl1 but only minimally to Vangl2. (b) Peptide pulldown assays using phosphorylated and non-phosphorylated HPV-16 E7 N29S CR2 peptides. Vangl1 binds strongly to the phosphorylated N29S peptide but not to its non-phosphorylated form. (c) Pulldown assays using phosphomimic HPV-16 E7 CR2 peptides in which CKII-targeted serines were substituted with aspartic acid. The phosphomimic fails to bind Vangl1. ‘ p’ indicates phosphorylation. (d) Co-immunoprecipitation of FLAG-Vangl1 with FLAG/HA-tagged HPV-16 E7 in HEK293 cells treated with the CKII inhibitor CX-4945. CKII inhibition markedly reduces Vangl1–E7 association. Beta galactosidase (β-gal) protein expression is used as a loading control in the western blotting analyses.

    Article Snippet: CaSki, HeLa, C-33A and HaCaT cells were transfected with siRNAs targeting Vangl1 (Dharmacon SMARTpool), AP1M1 (Dharmacon SMARTpool), HPV-16 E6/E7 (Eurofins), or Scramble control (Dharmacon siSTABLE) as previously described ( ).

    Techniques: Immunoprecipitation, Phospho-proteomics, Inhibition, Expressing, Control, Western Blot

    Immunoblot analysis of Vangl1 and E7 protein levels following siRNA-mediated knockdown of E6/E7 or Vangl1. (a, b) In HPV-16 E7-positive CaSki cells and HPV-18 E7-positive HeLa cells, E6/E7 depletion increases total Vangl1 abundance. (c, d) In HPV-negative C33A cells and non-transformed HaCaT keratinocytes, Vangl1 remains unchanged following E6/E7 knockdown. GAPDH expression is shown as loading control. Vangl1 band density was normalized to GAPDH band density, and the data was used to plot the densitometry graphs for all cell lines. Data is shown as the fold-changes of normalized Vangl1 levels relative to the control (siScramble) ± standard deviation. p values of 3 independent experiments were calculated by Student’s t test. ( p values of 3 independent experiments were calculated by Student’s t test. (*: p -value < 0.05; **: p -value <0.01; ***: p -value <0.001).

    Journal: bioRxiv

    Article Title: CKII-Phosphorylated HPV-16 E7 Disrupts Planar Cell Polarity by Recruiting Vangl1 Phospho-E7 Hijacks Vangl1 Trafficking

    doi: 10.64898/2026.02.25.707969

    Figure Lengend Snippet: Immunoblot analysis of Vangl1 and E7 protein levels following siRNA-mediated knockdown of E6/E7 or Vangl1. (a, b) In HPV-16 E7-positive CaSki cells and HPV-18 E7-positive HeLa cells, E6/E7 depletion increases total Vangl1 abundance. (c, d) In HPV-negative C33A cells and non-transformed HaCaT keratinocytes, Vangl1 remains unchanged following E6/E7 knockdown. GAPDH expression is shown as loading control. Vangl1 band density was normalized to GAPDH band density, and the data was used to plot the densitometry graphs for all cell lines. Data is shown as the fold-changes of normalized Vangl1 levels relative to the control (siScramble) ± standard deviation. p values of 3 independent experiments were calculated by Student’s t test. ( p values of 3 independent experiments were calculated by Student’s t test. (*: p -value < 0.05; **: p -value <0.01; ***: p -value <0.001).

    Article Snippet: CaSki, HeLa, C-33A and HaCaT cells were transfected with siRNAs targeting Vangl1 (Dharmacon SMARTpool), AP1M1 (Dharmacon SMARTpool), HPV-16 E6/E7 (Eurofins), or Scramble control (Dharmacon siSTABLE) as previously described ( ).

    Techniques: Western Blot, Knockdown, Transformation Assay, Expressing, Control, Standard Deviation

    (a) Immunoblot analysis of Vangl1 in CaSki cells transfected with control, Vangl1 or E6/E7 siRNAs and treated with the proteasome inhibitor CBZ, the lysosomal inhibitor chloroquine (CQ), or DMSO. E6/E7 knockdown alone increases Vangl1 levels more strongly than either inhibitor. (b) Cycloheximide chase assays in CaSki cells shows that Vangl1 half-life in control cells is longer than in E7-depleted cells. GAPDH expression is shown as loading control. Vangl1 band density was normalized to GAPDH band density, and the data was used to plot densitometry graphs for the cell lines. Data is shown as the fold changes of normalized Vangl1 levels relative to the control (siScramble) ± standard deviation. (c) Long exposure inset of the blot in (b) shows siScramble and siE6/E7 at similar start-point intensities, highlighting biphasic degradation of unphosphorylated and phosphorylated Vangl1 forms in siScramble cells. (d) Cycloheximide chase assays in HEK293 cells overexpressing Vangl1 with or without HPV-16 E7. Vangl1 half-life increases when co-expressed with E7. (e) Densitometry showing reciprocal stabilization of E7 by Vangl1. E7 half-life increases when co-expressed with Vangl1. Dotted lines on time-kinetic graphs indicate specific half-life. β-gal expression is shown as loading control. Vangl1 band density was normalized to the β-gal band density, and the data was used to plot a densitometry graph. Data is shown as the fold changes of normalized Vangl1 levels relative to the control (Vangl1 only) ± standard deviation. p values of 3 independent experiments were calculated by Student’s t test. ( p values of 3 independent experiments were calculated by Student’s t test. (*: p -value < 0.05; **: p -value <0.01; ***: p -value <0.001).

    Journal: bioRxiv

    Article Title: CKII-Phosphorylated HPV-16 E7 Disrupts Planar Cell Polarity by Recruiting Vangl1 Phospho-E7 Hijacks Vangl1 Trafficking

    doi: 10.64898/2026.02.25.707969

    Figure Lengend Snippet: (a) Immunoblot analysis of Vangl1 in CaSki cells transfected with control, Vangl1 or E6/E7 siRNAs and treated with the proteasome inhibitor CBZ, the lysosomal inhibitor chloroquine (CQ), or DMSO. E6/E7 knockdown alone increases Vangl1 levels more strongly than either inhibitor. (b) Cycloheximide chase assays in CaSki cells shows that Vangl1 half-life in control cells is longer than in E7-depleted cells. GAPDH expression is shown as loading control. Vangl1 band density was normalized to GAPDH band density, and the data was used to plot densitometry graphs for the cell lines. Data is shown as the fold changes of normalized Vangl1 levels relative to the control (siScramble) ± standard deviation. (c) Long exposure inset of the blot in (b) shows siScramble and siE6/E7 at similar start-point intensities, highlighting biphasic degradation of unphosphorylated and phosphorylated Vangl1 forms in siScramble cells. (d) Cycloheximide chase assays in HEK293 cells overexpressing Vangl1 with or without HPV-16 E7. Vangl1 half-life increases when co-expressed with E7. (e) Densitometry showing reciprocal stabilization of E7 by Vangl1. E7 half-life increases when co-expressed with Vangl1. Dotted lines on time-kinetic graphs indicate specific half-life. β-gal expression is shown as loading control. Vangl1 band density was normalized to the β-gal band density, and the data was used to plot a densitometry graph. Data is shown as the fold changes of normalized Vangl1 levels relative to the control (Vangl1 only) ± standard deviation. p values of 3 independent experiments were calculated by Student’s t test. ( p values of 3 independent experiments were calculated by Student’s t test. (*: p -value < 0.05; **: p -value <0.01; ***: p -value <0.001).

    Article Snippet: CaSki, HeLa, C-33A and HaCaT cells were transfected with siRNAs targeting Vangl1 (Dharmacon SMARTpool), AP1M1 (Dharmacon SMARTpool), HPV-16 E6/E7 (Eurofins), or Scramble control (Dharmacon siSTABLE) as previously described ( ).

    Techniques: Western Blot, Transfection, Control, Knockdown, Expressing, Standard Deviation

    (a) Subcellular fractionation of CaSki cells transfected with control or E6/E7 siRNAs. Vangl1 is absent from the cytoskeletal fraction in control cells, but becomes detectable upon E6/E7 knockdown. (b) GST pulldown assays showing that AP1M1 selectively binds phosphorylated HPV-16 E7. (c–d) Immunoblot analysis of CaSki and HeLa cells shows that Vangl1 abundance increases upon E6/E7 depletion and is further increased by AP1M1 knockdown. (e) Immunoblot analysis of HaCaT keratinocytes shows that neither E6/E7 knockdown nor AP1M1 knockdown results in increased Vangl1 levels. (f) Subcellular fractionation of CaSki cells after AP1M1 knockdown shows Vangl1 accumulation across cytoplasmic, membrane, and cytoskeletal compartments mirroring E6/E7 knockdown. GAPDH expression is shown as loading control. Vangl1 band density was normalized to GAPDH band density, and the data was used to plot densitometry graphs for the cell lines. Data is shown as the fold changes of normalized Vangl1 levels relative to the control (siScramble) ± standard deviation. p values of 3 independent experiments were calculated by Student’s t test. ( p values of 3 independent experiments were calculated by Student’s t test. (*: p -value < 0.05; **: p -value <0.01; ***: p -value <0.001).

    Journal: bioRxiv

    Article Title: CKII-Phosphorylated HPV-16 E7 Disrupts Planar Cell Polarity by Recruiting Vangl1 Phospho-E7 Hijacks Vangl1 Trafficking

    doi: 10.64898/2026.02.25.707969

    Figure Lengend Snippet: (a) Subcellular fractionation of CaSki cells transfected with control or E6/E7 siRNAs. Vangl1 is absent from the cytoskeletal fraction in control cells, but becomes detectable upon E6/E7 knockdown. (b) GST pulldown assays showing that AP1M1 selectively binds phosphorylated HPV-16 E7. (c–d) Immunoblot analysis of CaSki and HeLa cells shows that Vangl1 abundance increases upon E6/E7 depletion and is further increased by AP1M1 knockdown. (e) Immunoblot analysis of HaCaT keratinocytes shows that neither E6/E7 knockdown nor AP1M1 knockdown results in increased Vangl1 levels. (f) Subcellular fractionation of CaSki cells after AP1M1 knockdown shows Vangl1 accumulation across cytoplasmic, membrane, and cytoskeletal compartments mirroring E6/E7 knockdown. GAPDH expression is shown as loading control. Vangl1 band density was normalized to GAPDH band density, and the data was used to plot densitometry graphs for the cell lines. Data is shown as the fold changes of normalized Vangl1 levels relative to the control (siScramble) ± standard deviation. p values of 3 independent experiments were calculated by Student’s t test. ( p values of 3 independent experiments were calculated by Student’s t test. (*: p -value < 0.05; **: p -value <0.01; ***: p -value <0.001).

    Article Snippet: CaSki, HeLa, C-33A and HaCaT cells were transfected with siRNAs targeting Vangl1 (Dharmacon SMARTpool), AP1M1 (Dharmacon SMARTpool), HPV-16 E6/E7 (Eurofins), or Scramble control (Dharmacon siSTABLE) as previously described ( ).

    Techniques: Fractionation, Transfection, Control, Knockdown, Western Blot, Membrane, Expressing, Standard Deviation

    (a) Confocal microscopy of HEK293 cells expressing Vangl1 alone, HPV-16 E7 alone, or both proteins together, show diffuse, cytoplasmic Vangl1 with reduced cortical levels in cells expressing E7. Merged and zoomed images show co-localization of Vangl1 and E7 within intracellular compartments. (b) Brightfield images of CaSki spheroids following siRNA-mediated knockdown of E6/E7 or Vangl1 showing spheroids with pronounced structural disintegration, irregular edges, and reduced cohesion. (c) 3D surface plots of spheroids highlight architectural defects. Control spheroids show uniform signal intensity and well-defined boundaries, while E6/E7 and Vangl1 knockdown spheroids display diffuse signal, fragmented contours, and disrupted core organization. Micrographs were prepared using the Quickfigures plugin of ImageJ. The brightness of the panels was uniformly enhanced post image processing.

    Journal: bioRxiv

    Article Title: CKII-Phosphorylated HPV-16 E7 Disrupts Planar Cell Polarity by Recruiting Vangl1 Phospho-E7 Hijacks Vangl1 Trafficking

    doi: 10.64898/2026.02.25.707969

    Figure Lengend Snippet: (a) Confocal microscopy of HEK293 cells expressing Vangl1 alone, HPV-16 E7 alone, or both proteins together, show diffuse, cytoplasmic Vangl1 with reduced cortical levels in cells expressing E7. Merged and zoomed images show co-localization of Vangl1 and E7 within intracellular compartments. (b) Brightfield images of CaSki spheroids following siRNA-mediated knockdown of E6/E7 or Vangl1 showing spheroids with pronounced structural disintegration, irregular edges, and reduced cohesion. (c) 3D surface plots of spheroids highlight architectural defects. Control spheroids show uniform signal intensity and well-defined boundaries, while E6/E7 and Vangl1 knockdown spheroids display diffuse signal, fragmented contours, and disrupted core organization. Micrographs were prepared using the Quickfigures plugin of ImageJ. The brightness of the panels was uniformly enhanced post image processing.

    Article Snippet: CaSki, HeLa, C-33A and HaCaT cells were transfected with siRNAs targeting Vangl1 (Dharmacon SMARTpool), AP1M1 (Dharmacon SMARTpool), HPV-16 E6/E7 (Eurofins), or Scramble control (Dharmacon siSTABLE) as previously described ( ).

    Techniques: Confocal Microscopy, Expressing, Knockdown, Control

    (a) Brightfield representative images from 2D Matrigel invasion assays in CaSki cells show dense invasion in control cells, whereas Vangl1-depleted cells show markedly reduced invasion. (b) Quantification of invading cells using the ImageJ Cell counter tool confirms a significant decrease in invasion upon Vangl1 knockdown. (c) Brightfield images of spheroid invasion across increasing collagen content (Matrigel:Collagen 1:1 and 1:3) show collective invasion in control spheroids; (d) E6/E7-depleted spheroids fail to generate organized invasive protrusions in either matrix condition; (e) Vangl1-depleted spheroids similarly lack robust invasive structures and display matrix-dependent architectural defects. Corresponding 3D surface plots below the micrographs reflect spheroidal architectural integrity. Invasiveness of the spheroids was monitored for 7 days and imaged at 20x magnification. (f) Brightfield representative images from 2D Matrigel invasion assays following AP1M1 knockdown reveal a pronounced reduction in invasion. Invading cells in the 2D assays were stained with crystal violet and imaged using a brightfield microscope at 10x magnification. p values of 3 independent experiments were calculated by Student’s t test. (*: p -value < 0.05; **: p -value <0.01; ***: p -value <0.001; ****: p -value <0.0001). Micrographs were prepared using the Quickfigures plugin of ImageJ. The brightness of the panels was uniformly enhanced post-image processing.

    Journal: bioRxiv

    Article Title: CKII-Phosphorylated HPV-16 E7 Disrupts Planar Cell Polarity by Recruiting Vangl1 Phospho-E7 Hijacks Vangl1 Trafficking

    doi: 10.64898/2026.02.25.707969

    Figure Lengend Snippet: (a) Brightfield representative images from 2D Matrigel invasion assays in CaSki cells show dense invasion in control cells, whereas Vangl1-depleted cells show markedly reduced invasion. (b) Quantification of invading cells using the ImageJ Cell counter tool confirms a significant decrease in invasion upon Vangl1 knockdown. (c) Brightfield images of spheroid invasion across increasing collagen content (Matrigel:Collagen 1:1 and 1:3) show collective invasion in control spheroids; (d) E6/E7-depleted spheroids fail to generate organized invasive protrusions in either matrix condition; (e) Vangl1-depleted spheroids similarly lack robust invasive structures and display matrix-dependent architectural defects. Corresponding 3D surface plots below the micrographs reflect spheroidal architectural integrity. Invasiveness of the spheroids was monitored for 7 days and imaged at 20x magnification. (f) Brightfield representative images from 2D Matrigel invasion assays following AP1M1 knockdown reveal a pronounced reduction in invasion. Invading cells in the 2D assays were stained with crystal violet and imaged using a brightfield microscope at 10x magnification. p values of 3 independent experiments were calculated by Student’s t test. (*: p -value < 0.05; **: p -value <0.01; ***: p -value <0.001; ****: p -value <0.0001). Micrographs were prepared using the Quickfigures plugin of ImageJ. The brightness of the panels was uniformly enhanced post-image processing.

    Article Snippet: CaSki, HeLa, C-33A and HaCaT cells were transfected with siRNAs targeting Vangl1 (Dharmacon SMARTpool), AP1M1 (Dharmacon SMARTpool), HPV-16 E6/E7 (Eurofins), or Scramble control (Dharmacon siSTABLE) as previously described ( ).

    Techniques: Control, Knockdown, Staining, Microscopy

    (a) Brightfield images of CaSki spheroids following siRNA transfection and 48 h treatment with DMSO. Control spheroids remain compact and cohesive, whereas E6/E7- and Vangl1-depleted spheroids exhibit architectural changes; (b) Palbociclib treatment induces mild disintegration in siScramble spheroids, but causes pronounced disintegration in E6/E7- and Vangl1-depleted spheroids; (c–d) Cisplatin and Etoposide treatments show moderate disruption in siScramble spheroids, whereas E6/E7- and Vangl1-depleted spheroids undergo rapid dissociation and display debris-rich halos. The 3D surface plots of the spheroids are presented on the right panels. Brightfield images were acquired at 20x magnification. Micrographs and 3D surface plots were prepared using ImageJ. The brightness of the panels was uniformly enhanced post-image processing.

    Journal: bioRxiv

    Article Title: CKII-Phosphorylated HPV-16 E7 Disrupts Planar Cell Polarity by Recruiting Vangl1 Phospho-E7 Hijacks Vangl1 Trafficking

    doi: 10.64898/2026.02.25.707969

    Figure Lengend Snippet: (a) Brightfield images of CaSki spheroids following siRNA transfection and 48 h treatment with DMSO. Control spheroids remain compact and cohesive, whereas E6/E7- and Vangl1-depleted spheroids exhibit architectural changes; (b) Palbociclib treatment induces mild disintegration in siScramble spheroids, but causes pronounced disintegration in E6/E7- and Vangl1-depleted spheroids; (c–d) Cisplatin and Etoposide treatments show moderate disruption in siScramble spheroids, whereas E6/E7- and Vangl1-depleted spheroids undergo rapid dissociation and display debris-rich halos. The 3D surface plots of the spheroids are presented on the right panels. Brightfield images were acquired at 20x magnification. Micrographs and 3D surface plots were prepared using ImageJ. The brightness of the panels was uniformly enhanced post-image processing.

    Article Snippet: CaSki, HeLa, C-33A and HaCaT cells were transfected with siRNAs targeting Vangl1 (Dharmacon SMARTpool), AP1M1 (Dharmacon SMARTpool), HPV-16 E6/E7 (Eurofins), or Scramble control (Dharmacon siSTABLE) as previously described ( ).

    Techniques: Transfection, Control, Disruption

    A. Table of patient samples used in snRNA-seq, with the status of a few gene alterations listed. B. Sample MRIs from one patient showing T1 contrast-enhanced and T2 weighted images. On the left is the preoperative study demonstrating location of contrast enhancing zone (yellow arrow) containing the presumed solid tumor and the broader, T2-hyperintense signal (red arrow) that containing the presumed infiltrating tumor. The middle image shows the pre-operative regions selected for biopsy and the right image shows the intraoperative neuronavigation biopsy acquisition. C. The workflow from sample biopsy, processing, snRNA-sequencing, and data analysis. D. Bar plots of cell type proportions in the infiltrating and solid tumor regions. Each bar represents the mean proportion of the selected cell type in the region and the positive and negative standard deviation are represented by the bracket. Each dot represents the cell type proportion of a single sample. E. Representative images of expanded Nf1- knockout OPCs (GFP + PDGFRα + ) generated by transduction of MSCV carrying Nf1 guide RNA/Cas9. WT OPCs (GFP - PDGFRα + ) were excluded from the expanded Nf1 -null OPC clones, suggesting OPC competition. Scale bar: 50 μm. F. Representative images of expanded Rb -inactivated OPCs (GFP + PDGFRα + ) upon transduction of MSCV carrying HPV-16 E7 protein that inactivates Rb function. Expanded GFP + Rb -inactivated OPCs (orange arrow) intermixed with WT OPCs (GFP - PDGFRα + , white arrow-head), suggesting the lack of OPC competition. Scale bar: 50 μm G. Representative images showing the expansion of OPCs with EGFR mutation ( EGFRvIII ). The expanded clone of EGFRvIII -expressing OPCs excluded WT OPCs (GFP - PDGFRα + ), suggesting OPC competition. Scale bar: 50 μm. H. Summary of the sufficiency and insufficiency in driving OPC competition of all examined gliomagenic mutations in this study.

    Journal: bioRxiv

    Article Title: Critical role of cell competition in gliomagenesis

    doi: 10.64898/2026.01.15.699808

    Figure Lengend Snippet: A. Table of patient samples used in snRNA-seq, with the status of a few gene alterations listed. B. Sample MRIs from one patient showing T1 contrast-enhanced and T2 weighted images. On the left is the preoperative study demonstrating location of contrast enhancing zone (yellow arrow) containing the presumed solid tumor and the broader, T2-hyperintense signal (red arrow) that containing the presumed infiltrating tumor. The middle image shows the pre-operative regions selected for biopsy and the right image shows the intraoperative neuronavigation biopsy acquisition. C. The workflow from sample biopsy, processing, snRNA-sequencing, and data analysis. D. Bar plots of cell type proportions in the infiltrating and solid tumor regions. Each bar represents the mean proportion of the selected cell type in the region and the positive and negative standard deviation are represented by the bracket. Each dot represents the cell type proportion of a single sample. E. Representative images of expanded Nf1- knockout OPCs (GFP + PDGFRα + ) generated by transduction of MSCV carrying Nf1 guide RNA/Cas9. WT OPCs (GFP - PDGFRα + ) were excluded from the expanded Nf1 -null OPC clones, suggesting OPC competition. Scale bar: 50 μm. F. Representative images of expanded Rb -inactivated OPCs (GFP + PDGFRα + ) upon transduction of MSCV carrying HPV-16 E7 protein that inactivates Rb function. Expanded GFP + Rb -inactivated OPCs (orange arrow) intermixed with WT OPCs (GFP - PDGFRα + , white arrow-head), suggesting the lack of OPC competition. Scale bar: 50 μm G. Representative images showing the expansion of OPCs with EGFR mutation ( EGFRvIII ). The expanded clone of EGFRvIII -expressing OPCs excluded WT OPCs (GFP - PDGFRα + ), suggesting OPC competition. Scale bar: 50 μm. H. Summary of the sufficiency and insufficiency in driving OPC competition of all examined gliomagenic mutations in this study.

    Article Snippet: To inactivate Rb function, the HPV-16 E7 fragment was amplified from plasmid p1324 HPV-16 E7 (Addgene#8643) and cloned to replace Cas9 in MSCV vector, maintaining the in-frame fusion with T2A-EGFP for accurate reporting.

    Techniques: Sequencing, Standard Deviation, Knock-Out, Generated, Transduction, Clone Assay, Mutagenesis, Expressing

    A. Table of patient samples used in snRNA-seq, with the status of a few gene alterations listed. B. Sample MRIs from one patient showing T1 contrast-enhanced and T2 weighted images. On the left is the preoperative study demonstrating location of contrast enhancing zone (yellow arrow) containing the presumed solid tumor and the broader, T2-hyperintense signal (red arrow) that containing the presumed infiltrating tumor. The middle image shows the pre-operative regions selected for biopsy and the right image shows the intraoperative neuronavigation biopsy acquisition. C. The workflow from sample biopsy, processing, snRNA-sequencing, and data analysis. D. Bar plots of cell type proportions in the infiltrating and solid tumor regions. Each bar represents the mean proportion of the selected cell type in the region and the positive and negative standard deviation are represented by the bracket. Each dot represents the cell type proportion of a single sample. E. Representative images of expanded Nf1- knockout OPCs (GFP + PDGFRα + ) generated by transduction of MSCV carrying Nf1 guide RNA/Cas9. WT OPCs (GFP - PDGFRα + ) were excluded from the expanded Nf1 -null OPC clones, suggesting OPC competition. Scale bar: 50 μm. F. Representative images of expanded Rb -inactivated OPCs (GFP + PDGFRα + ) upon transduction of MSCV carrying HPV-16 E7 protein that inactivates Rb function. Expanded GFP + Rb -inactivated OPCs (orange arrow) intermixed with WT OPCs (GFP - PDGFRα + , white arrow-head), suggesting the lack of OPC competition. Scale bar: 50 μm G. Representative images showing the expansion of OPCs with EGFR mutation ( EGFRvIII ). The expanded clone of EGFRvIII -expressing OPCs excluded WT OPCs (GFP - PDGFRα + ), suggesting OPC competition. Scale bar: 50 μm. H. Summary of the sufficiency and insufficiency in driving OPC competition of all examined gliomagenic mutations in this study.

    Journal: bioRxiv

    Article Title: Critical role of cell competition in gliomagenesis

    doi: 10.64898/2026.01.15.699808

    Figure Lengend Snippet: A. Table of patient samples used in snRNA-seq, with the status of a few gene alterations listed. B. Sample MRIs from one patient showing T1 contrast-enhanced and T2 weighted images. On the left is the preoperative study demonstrating location of contrast enhancing zone (yellow arrow) containing the presumed solid tumor and the broader, T2-hyperintense signal (red arrow) that containing the presumed infiltrating tumor. The middle image shows the pre-operative regions selected for biopsy and the right image shows the intraoperative neuronavigation biopsy acquisition. C. The workflow from sample biopsy, processing, snRNA-sequencing, and data analysis. D. Bar plots of cell type proportions in the infiltrating and solid tumor regions. Each bar represents the mean proportion of the selected cell type in the region and the positive and negative standard deviation are represented by the bracket. Each dot represents the cell type proportion of a single sample. E. Representative images of expanded Nf1- knockout OPCs (GFP + PDGFRα + ) generated by transduction of MSCV carrying Nf1 guide RNA/Cas9. WT OPCs (GFP - PDGFRα + ) were excluded from the expanded Nf1 -null OPC clones, suggesting OPC competition. Scale bar: 50 μm. F. Representative images of expanded Rb -inactivated OPCs (GFP + PDGFRα + ) upon transduction of MSCV carrying HPV-16 E7 protein that inactivates Rb function. Expanded GFP + Rb -inactivated OPCs (orange arrow) intermixed with WT OPCs (GFP - PDGFRα + , white arrow-head), suggesting the lack of OPC competition. Scale bar: 50 μm G. Representative images showing the expansion of OPCs with EGFR mutation ( EGFRvIII ). The expanded clone of EGFRvIII -expressing OPCs excluded WT OPCs (GFP - PDGFRα + ), suggesting OPC competition. Scale bar: 50 μm. H. Summary of the sufficiency and insufficiency in driving OPC competition of all examined gliomagenic mutations in this study.

    Article Snippet: To inactivate Rb function, the HPV-16 E7 fragment was amplified from plasmid p1324 HPV-16 E7 (Addgene#8643) and cloned to replace Cas9 in MSCV vector, maintaining the in-frame fusion with T2A-EGFP for accurate reporting.

    Techniques: Sequencing, Standard Deviation, Knock-Out, Generated, Transduction, Clone Assay, Mutagenesis, Expressing